October 9, 2015
Roche buys Adheron
A research-based healthcare company, Roche, has bought Adheron Therapeutics
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 9, 2015
FDA Accepts Allergan’s Supplemental New Drug Application (sNDA) for DALVANCE
Allergan plc has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Allergan’s supplemental New Drug Application (sNDA), for MRSA.
October 8, 2015
New NIH breast cancer research focuses on prevention
National Institutes of Health (NIH) has launched a new phase of the Breast Cancer and the Environment Research Program (BCERP), focused on prevention.
October 8, 2015
US FDA announces updated drug shortages list
U.S. Food & Drug Administration (FDA) has updated information on Drug Shortages.
October 8, 2015
Verona Pharma welcomes new directors to the company
Verona Pharma plc, a London-listed drug development company focused on medicines to treat respiratory diseases, has appointed new Non-Executive Directors of the Company
October 8, 2015
Lilly Receives FDA Breakthrough Therapy Designation for Abemaciclib in Advanced Breast Cancer
Eli Lilly and Company has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to…
October 8, 2015
Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
Merck KGaA and Pfizer have announced that the US Food and Drug Administration (FDA) has granted avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer.
October 8, 2015
Novartis:Long-term efficacy of Gilenya
Novartis has announced a new analysis from the phase III FREEDOMS and FREEDOMS II trials reinforcing the long-term efficacy profile of Gilenya (fingolimod).
October 8, 2015
Sanofi and Genzyme:positive investigational data from the extension study of Lemtrada
Sanofi and its subsidiary Genzyme announced positive new five-year investigational data from the extension study of Lemtrada (alemtuzumab) for patients with relapsing remitting multiple sclerosis (RRMS).